01891nas a2200313   4500000000100000008004100001260001700042653001000059653001700069653001800086653002100104653002000125653001100145653002300156653002500179653000900204653001500213653001600228653001000244100001200254700002100266700001500287700001400302245010800316300000900424490000700433520112300440022001401563       2010                            d  c2010 Mar-Apr10aAdult10aEar Diseases10aEar, External10aErythema Nodosum10aGlucocorticoids10aHumans10aLeprostatic Agents10aLeprosy, lepromatous10aMale10aPrednisone10aThalidomide10aThigh1 aSaber M1 aBourassa-Fulop C1 aBouffard D1 aProvost N00aCanadian case report of erythema nodosum leprosum successfully treated with prednisone and thalidomide.  a95-90 v143 a<p><b>BACKGROUND: </b>Erythema nodosum leprosum (ENL) is a disease rarely encountered in Canada. It is characterized by multiple remissions and recurrences, often requires long-term treatment, and can result in debilitating sequelae.</p><p><b>OBJECTIVE: </b>To promote rapid recognition and adequate therapy for ENL.</p><p><b>METHODS: </b>Case report of a 39-year-old man diagnosed with an ENL. The clinical and histopathologic features, treatment provided, and response to treatment are detailed in this article.</p><p><b>RESULTS: </b>ENL presented itself as painful cutaneous lesions on the face and limbs, bilateral paresthesia of the fourth and fifth fingers, and systemic symptoms. Prednisone 40 mg daily for a week and then 60 mg daily for another week reduced the lesions by 80% and the pain by 50%. Although prednisone 60 mg daily was continued for one more week and then stopped, thalidomide was started at a dose of 300 mg daily for 4 weeks and then reduced gradually, which led to complete resolution.</p><p><b>CONCLUSION: </b>At the 7(1/2)-month follow-up, the patient remained completely asymptomatic.</p>  a1203-4754